Otolaryngology Doctors in Troy, MI Accepting Medicare

8 Otolaryngology doctors found. Showing 1 - 8

Ross Mayerhoff, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1560 E Maple Rd, Suite 200, Troy, MI 48083 Phone: 248-581-5200    Fax: 248-581-5299

Dr. Homaira N Danish, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 4600 Investment Dr, Ste 360, Troy, MI 48098 Phone: 248-267-5004    Fax: 248-267-5007

David M Kent, D.O. Otolaryngology - Facial Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 100 Kirts Blvd, Troy, MI 48084 Phone: 248-519-9127

Dr. Ranga Reddy Sirigiri, M.D. Otolaryngology - Pediatric Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 660 Trombley Dr, Troy, MI 48083 Phone: 586-439-5729

Dr. Andrew M Compton, MD Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1639 E Big Beaver Rd Ste 103, Troy, MI 48083 Phone: 248-289-7300    Fax: 248-289-7301

Andrew William Joseph, M.D. Otolaryngology - Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3940 John R Rd, Troy, MI 48083 Phone: 947-217-3223

Jeffrey J Colton, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 4550 Investment Dr, 290, Troy, MI 48098 Phone: 248-267-9700    Fax: 248-267-9711

Theodore Alan Golden, MD Otolaryngology - Facial Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 755 W Big Beaver, Suite 2111, Troy, MI 48084 Phone: 248-362-2345    Fax: 248-362-1910

News Archive

Metabasis Therapeutics receives notice letter from Nasdaq

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

Scientists track SARS-CoV-2 in wastewater

Epidemiologist David Larsen, from Syracuse University and microbiologists Hyatt Green, from the College of Environmental Science and Forestry and Frank Middleton, from Upstate Medical University are lead members of a multi-institution research project that is expected to have global application in future efforts to track and contain Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus Disease 2019 (COVID-19).

Deep genome sequencing used to predict clinical outcomes in patients with breast cancer tumors

New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients.

Read more Medical News

› Verified 2 days ago